登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验,由首都医科大学附属北京朝阳医院牵头,本站收录的另外 4 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 5
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 牵头方首都医科大学附属北京朝阳医院Beijing Chao-Yang Hospital北京医院页面
- 研究中心首都医科大学附属北京友谊医院Beijing Friendship Hospital北京医院页面
- 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
- 研究中心北京大学第三医院Peking University Third Hospital北京医院页面
- 研究中心中南大学湘雅三医院Third Xiangya Hospital长沙医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07882628,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Pathological/clinical diagnosis: Definitive pathological diagnosis after surgical resection is required as the gold standard.
入选标准第 6 条
Performance status: Able to tolerate bronchoscopic biopsy, with no contraindications to biopsy.
入选标准第 10 条
Nodule characteristics: Single or multiple pulmonary nodules detected on thin-section CT (slice thickness ≤1.5 mm). The target lesion planned for biopsy has a maximum diameter ≥8 mm and ≤30 mm.
入选标准第 11 条
Clinician assessment: Clinicians recommend bronchoscopic biopsy (including conventional bronchoscopy, endobronchial ultrasound [EBUS], navigational bronchoscopy, etc.) to determine the pathological nature of the pulmonary nodule.
入选标准第 12 条
Specimen and imaging: Small tissue specimens obtained during biopsy undergo three-dimensional interferometric imaging, and complete imaging data are retained.
入选标准第 13 条
Pathological/clinical diagnosis: Definitive pathological diagnosis of the small biopsy specimen is required as the gold standard.
入选标准第 14 条
Prior anti-tumor treatment: Any form of anti-tumor therapy received within the past 6 months, including chemotherapy, radiotherapy, targeted therapy, or immune checkpoint inhibitor therapy.
排除标准第 3 条
Prior anti-tumor treatment: Any form of anti-tumor therapy received within the past 6 months, including chemotherapy, radiotherapy, targeted therapy, or immune checkpoint inhibitor therapy.
排除标准第 11 条
Performance status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
入选标准第 2 条
Nodule characteristics: Single or multiple pulmonary nodules detected on thin-section CT (slice thickness ≤1.5 mm). The largest diameter of the primary lesion is ≥8 mm and ≤20 mm. For patients with multiple nodules, the maximum diameter of other lesions must be <8 mm.
入选标准第 3 条
Other malignant tumors: History of other malignant tumors within the past 3 years.
排除标准第 5 条
Special population: Pregnant or breastfeeding women.
排除标准第 7 条
Special population: Pregnant or breastfeeding women.
排除标准第 12 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07882628,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age: 18-75 years. Performance status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Nodule characteristics: Single or multiple pulmonary nodules detected on thin-section CT (slice thickness ≤1.5 mm). The largest diameter of the primary lesion is ≥8 mm and ≤20 mm. For patients with multiple nodules, the maximum diameter of other lesions must be <8 mm. No clinical or imaging evidence of lymph node or distant metastasis. Planned surgical resection: Patients with complete clinical data and preoperative thin-section CT; peripheral blood samples can be collected. Pathological/clinical diagnosis: Definitive pathological diagnosis after surgical resection is required as the gold standard. Informed consent: Patients voluntarily join this study, sign written informed consent, and agree to complete scheduled follow-up for at least 5 years. Sample availability: Patients can provide sufficient peripheral blood samples as required by the study protocol. For patients undergoing surgery or biopsy, tumor tissues and adjacent normal tissue samples meeting quality requirements can be obtained. Age: 18-75 years. Performance status: Able to tolerate bronchoscopic biopsy, with no contraindications to biopsy. Nodule characteristics: Single or multiple pulmonary nodules detected on thin-section CT (slice thickness ≤1.5 mm). The target lesion planned for biopsy has a maximum diameter ≥8 mm and ≤30 mm. Clinician assessment: Clinicians recommend bronchoscopic biopsy (including conventional bronchoscopy, endobronchial ultrasound [EBUS], navigational bronchoscopy, etc.) to determine the pathological nature of the pulmonary nodule. Specimen and imaging: Small tissue specimens obtained during biopsy undergo three-dimensional interferometric imaging, and complete imaging data are retained. Pathological/clinical diagnosis: Definitive pathological diagnosis of the small biopsy specimen is required as the gold standard. Informed consent: Patients voluntarily join this study, sign written informed consent, and agree to complete scheduled follow-up for at least 5 years.排除标准:Exclusion Criteria:
Concurrent immune diseases: Active autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.), or patients receiving long-term systemic immunosuppressants or glucocorticoids within the past 6 months. Active infection: Active infections (such as active pulmonary tuberculosis, acute phase of SARS-CoV-2 infection, etc.) that may significantly affect immune status. Prior anti-tumor treatment: Any form of anti-tumor therapy received within the past 6 months, including chemotherapy, radiotherapy, targeted therapy, or immune checkpoint inhibitor therapy. Suspected multiple primary lung cancers where secondary lesions require simultaneous or staged intervention (surgery, ablation, radiotherapy, etc.). Other malignant tumors: History of other malignant tumors within the past 3 years. Severe dysfunction of major organs: Severe hepatic or renal insufficiency (judged by investigators). Special population: Pregnant or breastfeeding women. Poor study compliance: Any psychological, family, or social factors that prevent patients from understanding and following the study protocol and follow-up plan. Concurrent immune diseases: Active autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.), or patients receiving long-term systemic immunosuppressants or glucocorticoids within the past 6 months. Active infection: Active infections (such as active pulmonary tuberculosis, acute phase of SARS-CoV-2 infection, etc.) that may significantly affect immune status. Prior anti-tumor treatment: Any form of anti-tumor therapy received within the past 6 months, including chemotherapy, radiotherapy, targeted therapy, or immune checkpoint inhibitor therapy. Special population: Pregnant or breastfeeding women. Poor compliance with study or procedure: Any physical, psychological, family, or social factors that prevent patients from understanding and following the study protocol or tolerating bronchoscopy. Bleeding tendency or severe coagulation disorders.
引自 ClinicalTrials.gov, NCT07882628, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07882628,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。